Asunto(s)
Dermatán Sulfato/uso terapéutico , Fibrinolíticos/uso terapéutico , Trombosis/prevención & control , Animales , Coagulación Sanguínea/efectos de los fármacos , Pruebas de Coagulación Sanguínea , Dermatán Sulfato/administración & dosificación , Dermatán Sulfato/farmacocinética , Dermatán Sulfato/farmacología , Evaluación de Medicamentos , Evaluación Preclínica de Medicamentos , Fibrinolíticos/administración & dosificación , Fibrinolíticos/farmacocinética , Fibrinolíticos/farmacología , Cofactor II de Heparina/metabolismo , Humanos , Infusiones Intravenosas , Inyecciones Intramusculares , Inyecciones Intravenosas , Inyecciones Subcutáneas , Conejos , Ratas , Diálisis Renal , Porcinos , Trombina/metabolismo , Terapia Trombolítica , Trombosis/tratamiento farmacológicoRESUMEN
An anabolic hormone, methandrostenolone, was shown to be able to decrease significantly the cicatrization-time on animals with induced sperimental acute myocardial infarction (AMI). A controlled clinical trial was performed on group of 246 patients affected by AMI, giving them methandrostenolone at dose of 25 mg im.m. per day, for the first ten days from the beginning of symptoms. An omogeneous group of 240 patients with AMI was used as control. The mortality rate resulted 13,4% in the treated group 18,7% in the control's. 10 patients in the treated group (4,2%) died of cardiac failure versus 17 (7,1%) in the control group, 9 (3,7%) of cardiac rupture in the former versus 6 (2,4%) in the latter. As far as these differences are concerned statistical significance was not reached. A larger number of patients would be requested.